Symptom severity assessed by NYHA functional class and QRS duration are essential criteria for selection of heart failure (HF) patients for CRT. This study assessed the relationship between NYHA class, QRS duration, and survival in a nationwide HF registry. 
Introduction
Heart failure (HF) is a highly symptomatic syndrome and associated with poor quality of life, frequent hospitalizations, and a high mortality risk despite recent advances in treatment with drugs and devices. 1, 2 It is estimated that 2-3% of the population in industrialized countries suffers from HF, with a marked rise in those aged above 65. 3, 4 In 1928 the New York Heart Association published a classification of HF symptom severity relating cardinal symptoms of HF like shortness of breath and fatigue to the levels of physical activity on which they occur (NYHA functional class I-IV). 5 Despite well-known limitations such as the temporal variability of clinical findings, interoperator variation, and a poor correlation with measures of cardiac function, 6, 7 the NYHA classification is universally used to grade symptoms and select therapy in clinical practice, and provides prognostic discrimination close to that of complex multivariable risk models. 8 A wide QRS complex on the surface ECG, especially if displayed as an LBBB, indicates intraventricular dyssynchony, and is a marker of poor prognosis in HF. 9 Cardiac resynchronization therapy improves survival, functional capacity, and quality of life in selected patients with such ECG abnormalities. Following early pivotal trials establishing the effectiveness of CRT in NYHA class III and IV, 10,11 the concept of resynchronization was expanded to patients with mild HF.
12 -14 Current guidelines recommend CRT for patients with HF in NYHA class II-IV, 15 -17 with gradual differentiations in relation to QRS morphology and duration. Based on evidence from trials and meta-analyses, patients with a typical LBBB pattern are given the highest level of recommendation.
18,19
A recent individual patient meta-analysis, however, suggested QRS duration rather than morphology as an independent predictor of CRT outcomes. 20 The implementation of CRT guidelines shows wide national and regional variation. 21 Potential differences in the adoption of CRT in NYHA class II compared with class III-IV have not been explored.
Since NYHA class and QRS morphology and duration form essential selection criteria, it would be important to study the relationship between these variables and survival in CRT candidates. However, this has been difficult as randomized studies largely included patients with either NYHA class III-IV or NYHA class (I and) II. Furthermore, the impact of QRS characteristics on survival in different groups of NYHA class is confounded by many other variables. Thus, large samples with information on a wide spectrum of baseline variables would be required to reach valid conclusions. Therefore, we investigated the interaction between NYHA class, QRS morphology/duration, and survival in a large Swedish HF registry with information from long-term follow-up and complete survival status by linkage to the National Population Registry.
Methods
The Swedish Heart Failure Registry (SwedeHF) has been described previously. 22, 23 Including over 63 000 unique HF patients, it is one of the largest HF registries worldwide. The protocol, case report form, and annual registry reports are available at http://www.SwedeHF.se. Patients with clinician-judged HF are included at discharge from hospital or upon outpatient visits at cardiology or internal medicine units and primary care clinics. Approximately 80 variables are recorded. The HF registry in general as well as the present study conform to the Declaration of Helsinki and they were approved by the responsible ethics committees. Individual patient consent is not required, but patients are informed of entry into national registries and allowed to opt out.
Patients
Figure 1 provides details on patient inclusion and exclusion. Between 11 May 2000 and 5 June 2013, there were 85 291 registrations from inpatient and outpatient units at 68 of 94 hospitals and from 102 of ∼1000 primary care outpatient clinics in Sweden. Coverage in 2012 was 55%. This was defined as the number of individuals reported to the registry divided by the sum of individuals with clinical HF encountered in Sweden according to ICD-10 (International Classification of Diseases-10th revision) code for HF plus those reported to the registry (to capture those few who may have been missed by ICD-10 code).
Survival status was updated monthly by linkage with the Swedish population registry (latest update 15 May 2013). For the purpose of this study, we included first registrations from patients with HF and reduced EF, defined as an EF ≤40%. Patients had to be in NYHA class II, III, or IV, with complete data on age, rhythm, device implantation status, as well as QRS duration and morphology. Patients with a prolonged QRS duration of ≥120 ms were defined as either LBBB or non-LBBB type at the discretion of the physician. We excluded repeat registrations and patients with a pacemaker or implantable cardioverter defibrillator (ICD) without a CRT component.
Analyses
The analysis of the inter-relationship between NYHA class, QRS duration, and survival was performed after the exclusion of patients with a CRT and, thus, paced QRS complexes on the ECG (Figure 1) , whereas the analysis of CRT utilization included patients with a CRT device.
Categorization and availability of data in the registry do not allow a perfect match with European Society of Cardiology (ESC) guidelines. 15 -17 Therefore, we evaluated four different scenarios to account for different levels of recommendation in the guidelines and different strengths of fitting between guideline criteria and registry variables. In the registry, EF is reported as <30, 30-39, 40-49, and ≥50%. As EF in Sweden is overwhelmingly reported in 5-10% increments, we assumed that most patients registered in the group with EF 30-39% had an actual EF of 30% or 35% and that few had an EF of 36-39%. In contrast, when selecting only registry patients with EF <30%, all would fulfil the LVEF guideline criterion for CRT, but some patients with EF 30-35% would be missed.
The strength of evidence and recommendations for CRT varies depending on QRS duration (120-149; ≥150 ms), QRS morphology (LBBB vs. non-LBBB), and rhythm (sinus vs. AF). Therefore, we performed analyses with progressively stricter CRT selection criteria, based on the guideline-specified recommendations I-A, I-B, IIa-B, and IIb-B from the European Heart Rhythm Association Guidelines 2013. 16 Guidelines also recommend CRT in patients with an indication for conventional ventricular pacing. The registry contains data on the presence of conventional pacemakers but not on the original indication for implantation or the percentage of ventricular pacing. Therefore, this potential guideline indication was not taken into account and patients with a previous pacemaker were excluded. Scenario 1: sinus rhythm (NYHA II-IV, EF <40%, QRS ≥120 ms regardless of QRS morphology) or AF (NYHA III-IV, EF <40%, QRS ≥120 ms regardless of QRS morphology) Scenario 2: sinus rhythm (NYHA II-IV, EF <40%, LBBB or QRS ≥150 ms) or AF (NYHA III-IV, EF <40%, LBBB, or QRS ≥150 ms) Scenario 3: sinus rhythm (NYHA II-IV, EF <30%, LBBB, or QRS ≥150 ms) or AF (NYHA III-IV, EF <30%, or QRS ≥150 ms) Scenario 4: sinus rhythm (NYHA II-IV, EF <30%, QRS ≥150 regardless of QRS morphology) or AF (NYHA III-IV, EF <30%, QRS ≥150 regardless of QRS morphology) (patients were only included after 1 January 2011 because evidence in NYHA II was not available before then).
Statistical analysis
All analyses were performed in R version 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria). The level of significance was set to 5% and all reported P-values are two-tailed.
Survival for narrow QRS, non-LBBB QRS prolongation, and LBBB was presented using the Kaplan-Meier method and groups were compared with the log-rank test, separately for patients with NYHA class II and III-IV. Univariable and multivariable Cox regressions, using the Efron method for tie handling, were performed for non-LBBB/LBBB as a categorical variable compared with narrow QRS with adjustment for the 40 variables listed in the Supplementary material online, Table  S1 , and the interaction between NYHA class and QRS morphology. The modelling of an interaction effect renders a similar interpretation as if the data had been analysed separately in NYHA class subgroups, but with the additional benefit of also being able statistically to test differences between groups of NYHA class in effects of non-LBBB and LBBB vs. narrow QRS on mortality. The proportional hazards assumption was investigated for the scaled Schoenfeld residuals from the multivariable models, and the dfbetas [a measure of how much the hazard ratio (HR) changes owing to the deletion of a single observation] from the models were inspected to detect extreme outliers. As a result, location (inpatient vs. outpatient) and marital status were modelled as strata variables because they were deemed not to fulfil the proportional hazard assumption. All continuous variables were modelled using restricted cubic splines (enabling possible non-linear relationships between these variables and the outcome to be modelled) with four degrees of freedom. 24 Some baseline variables had missing data. Table S1 in the Supplementary material online specifies 40 clinically relevant baseline variables and percentage missing for each variable. In the multivariable Cox regressions, to avoid bias and confounding resulting from variables not missing completely at random, multiple imputation (n = 10) was performed for all variables with missing data, using predictive mean matching with QRS width as a continuous variable and the 40 variables in Table S1 in the Supplementary material online, and the outcome, survival, included as the Nelson-Aalen estimator in the imputation model, although not imputed itself because it contained no missing values. Imputation corrections to the resulting standard errors were performed.
Results
Of 85 291 entries in the registry, 13 423 unique patients fulfilled the selection criteria ( Figure 1 ). Of these, 889 had a CRT device implanted including 447 with an ICD component, leaving 12 534 patients without CRT for the main analysis. Baseline characteristics are provided in Table 1 (for a complete list of variables see Table S1 in the Supplementary material online). There were 6377 patients (51%) with NYHA class II and 6157 (49%) in NYHA class III-IV. Patients in NYHA class II were younger, more likely to be male, and had a shorter duration of HF, less ischaemic cardiomyopathy, and a higher LVEF. Furthermore, they had a lower propability of AF, a lower heart rate, higher systolic blood pressure, and a more favourable co-morbidity profile. Levels of NT-proBNP were lower, while haemoglobin and creatinine clearance were higher. Interestingly, a higher proportion of NYHA class II patients were on treatment with ACE inhibitors and beta-blockers. QRS duration and morphology in relation to New York Heart Association class QRS prolongation was common in both groups (Figure 2) . On average, patients in NYHA class II compared with NYHA class III-IV had a somewhat smaller QRS (116 ± 29 ms vs. 119 ± 29 ms; P < 0.001) and fewer had a QRS of ≥120 ms (37% vs. 44%; P < 0.001), a QRS ≥150 ms (16% vs. 18%, P = 0.009), or an LBBB (23% vs. 28%; P < 0.001). However, among those with a QRS duration ≥120 ms, the proportion of patients with LBBB was similar: 64% in NYHA class II and 63% in NYHA class III-IV (P = 0.55), and increased with progressively wider QRS.
Survival in relation to New York Heart Association class and QRS duration and morphology
As expected, NYHA class II patients had a better survival compared with those in NYHA class III-IV (Figure 3 ). In the resulting multivariable Cox model, the HR and 95% confidence interval (CI) for mortality in NYHA III-IV vs. II was 1.31, 95% CI 1.23-1.40 (P < 0.001). In both groups, prolonged QRS duration was associated with worse survival and the prognosis of patients with a non-LBBB morphology was inferior compared with those who had LBBB. The proportion of patients surviving at 1, 3, and 5 years is given in Table 2 . After 5 years, 58% of patients in NYHA class II with QRS prolongation of non-LBBB type were alive, while the corresponding number of NYHA class III-IV patients was only 30%. In contrast, 69% and 49% of patients in NYHA class II and III-IV, respectively, survived at 5 years, if they had a narrow QRS. Table 1 , there were significant differences in baseline characteristics probably explaining the better outcome in NYHA class II vs. NYHA class III-IV patients. Thus, to assess the independent contribution of QRS duration and morphology to the mortality risk in NYHA class II and NYHA class III-IV, survival data were adjusted for important confounding variables. These factors had been specified a priori and included all variables with statistical differences shown in Table 1 and, in addition, civil status, housing, recruitment in or out of hospital, year of recruitment, setting of general follow-up, setting of HF follow-up, mean arterial pressure, pulse pressure, cardiomegaly, and/or congestion on X-ray.
As shown in
In all settings, prolonged QRS duration was associated with a significant increase in mortality risk (Figure 4) . After adjustment for multiple confounders, the HR for mortality in patients with non-LBBB type vs. narrow QRS was 1.19 (95% CI 1.05 − 1.36; P = 0.009) in NYHA class II and 1.33 (95% CI 1.21-1.47; P < 0.001) in NYHA class III-IV. Similarly, comparing patients with LBBB vs. narrow QRS, the adjusted HR was 1.16 (95% CI 1.03-1.41; P = 0.013) in NYHA class II and 1.12 (95% CI 1.02-1.22; P = 0.014) in NYHA class III-IV. Thus, QRS prolongation, both of LBBB and non-LBBB type, independently added a similar mortality risk in patients with NYHA class II and NYHA class III-IV (P for interaction: 0.521, crude and 0.244, adjusted). 
Eligibility and utilization of cardiac resynchronization therapy according to New York Heart Association class
The proportion of patients eligible for CRT and the actual utilization of CRT in relation to current guideline recommendations was analysed in 13 423 individual patients, including those with an implanted CRT device. Eligibility was analysed in four scenarios representing increasing strength of recommendation and fit between guideline and registry criteria ( Figure 5) Of patients meeting criteria for CRT, only a minority had actually received a device. This proportion ranged between 14.4% and 42.6% of eligible patients (4.4% and 6.2% of the total) with NYHA class II, and between 18.0% and 45.4% (8.6% and 8.8% of the total) in those with NYHA class III-IV. For example, in scenario 3, 27.1% and 31.4% had actually been implanted. Thus, irrespective of analysis, large proportions of both NYHA groups lacked CRT despite an indication. Consistently, the proportion of patients in NYHA class II who had an indication but were not treated with a device was lower compared with those in NYHA class III-IV, including scenario 4 which contained only patients who entered the registry after the first publication of CRT guidelines for NYHA class II patients in 2010. However, while the difference in CRT utilization was statistically significant in scenario 1-3, it did not reach statistical significance (P = 0.507) in the fourth scenario, evaluating only a total of 684 patients with an indication.
Discussion
Grading of HF symptoms according to the NYHA classification is a cornerstone in the clinical assessment of HF patients and has important clinical implications for the selection of appropriate treatment. Specifically, current guidelines for CRT tailor recommendations in relation to NYHA class and QRS characteristics.
15,16
We analysed the relationship between NYHA class, QRS duration/morphology, and survival in a large group of HF patients with reduced LVEF <40% and long-term follow-up via Swedish national registries. A QRS prolongation of ≥120 ms was common in both NYHA class II (36%) and NYHA class III-IV (44%). Importantly, while NYHA II patients were healthier at baseline and survived longer, the independent risk attributable to QRS prolongation of . LBBB or non-LBBB type was similar in NYHA class II and III-IV. Although CRT is highly recommended in current guidelines, only a minority of patients fulfilling guideline recommendations had received a device, and this underutilization appeared to be even greater in NYHA class II compared with NYHA class III-IV. Our finding that QRS duration is associated with a similar hazard for death in patients with NYHA class II and III-IV gains particular strength by the large sample size, the long and complete follow-up through national registries, and a background medical therapy reflecting a high standard of care. Even after adjustment for a large number of confounders, the mortality risk in NYHA class II patients with LBBB and non-LBBB morphology was significantly increased. This supports the notion that QRS prolongation is not only a general marker of HF severity 25 but also a risk factor contributing to the adverse prognosis in HF independently of other prognostic factors, presumably through the induction of ventricular dyssynchrony.
Other studies have looked into the interaction between NYHA class, QRS duration, and prognosis. Two smaller studies also found a wider QRS duration with more advanced NYHA class, but multivariable analysis was not performed. 26, 27 Similarly to the present study, a secondary analysis of a previous, smaller SwedeHF cohort indicated that interactions between QRS width and NYHA class were not significant upon multivariate analysis. 9 The proportion of patients with prolonged QRS ≥120 ms in our study (41%) corresponds well with previous reports. A broad QRS was also found in 41% of patients with an LVEF ≤35% evaluated in the EuroHeart failure survey, 28 37% of patients in the Italian Network on CHF 29 (using 140 ms as a cut-off), and 34% of HF patients examined in the setting of a community HF clinic. 30 In the present study, there was a trend towards worse prognosis in subjects with non-LBBB morphology, found in approximately one-third of patients with prolonged QRS, compared with LBBB. Causing a characteristic U-shaped activation pattern of the left ventricle, 31 LBBB has been closely linked to left intraventricular dyssynchrony between the septum and the lateral wall, while QRS prolongation of non-LBBB type may result in various other electromechanical abnormalities. 32 This may explain why patients with LBBB have especially large effects by CRT while non-LBBB morphology is a predictor of non-response. 33 Among patients with non-LBBB morphology, we could not single out those with a right bundle branch block (RBBB). RBBB is associated with increased mortality in chronic HF, 34 but RBBB patients do not improve by CRT. 35 Cardiac resynchronization therapy was first introduced in patients with NYHA class III. provided they had not been hospitalized during the month before enrolment and had an estimated survival exceeding 6 months.
11
This subgroup showed a significant reduction in the combined primary study endpoint, and hence the indication of 'ambulatory' NYHA class IV was incorporated into current guidelines. However, NYHA class IV is a rare indication in clinical practice and patients hospitalized with acutely decompensated HF and/or receiving inotropic support are usually not considered for implantation. In the European CRT survey, only 8% were judged to be in NYHA class IV at baseline. 38 In the present study, a total of 4.8% had NYHA class IV. Considering the clinical context in which patients are recruited to the registry, we assume that most of them met the criteria of 'ambulatory' class IV.
Utilization of CRT in NYHA class II vs. III-IV was significantly worse in scenarios 1-3. This can be explained by the later introduction of NYHA II to CRT guidelines. The analysis in scenario 4, focusing on a smaller sample of patients with strict indications recruited after 2010, showed a similarly worse utilization but the difference was not significant. In a registry, some appropriate reasons to abstain from device therapy such as high biological age, clinical severity of co-morbidities, or patient refusal are difficult to discern. However, considering the baseline characteristics (Table 1) , factors such as high age and severe co-morbidities are unlikely to explain the larger underutilization of CRT in NYHA class II.
In contrast to the poor utilization of CRT, a total of 94% and 91% received ACE inhibitors (or ARBs) and beta-blockers, respectively. Fewer patients in NYHA class III-IV were treated with these drugs, while they more often received diuretics and mineralocorticoids. In contrast to the poor utilization of CRT, a total of 94% and 91% received ACE inhibitors (or ARBs) and beta-blockers, respectively. Fewer patients in NYHA class III-IV were treated with these drugs, while they more often received diuretics and mineralocorticoids. It may be speculated that it was easier to achieve drug target doses in those with mild HF, better renal function, and less compromised haemodynamics as reflected by higher blood pressure.
Only half of the patients received CRT together with a defibrillator, which is below the European average but in keeping with Swedish implantation statistics and on a similar level compared with countries such as the UK or Denmark. 21 Our findings have clinical implications as they indicate that a wide QRS complex should alert physicians to the significantly increased mortality risk of the HF patient regardless of NYHA class and other conditions. Device treatment with CRT and, in most cases ICD, has strong evidence in this scenario and should be seriously considered. Studies indicate that CRT is similarly effective in appropriately selected NYHA class II and III-IV patients to improve outcomes.
14 As CRT appears particularly underutilized in NYHA class II, the value of early interventions to prevent disease progression should be highlighted. Recently, long-term effects of CRT on mortality 39 and measures of functional and LV remodelling 40 were shown in mild HF. However, these improvements were largely confined to patients with LBBB. Thus, our results also emphasize a particular need for additional treatment options in patients with mild to moderate HF and QRS prolongation of non-LBBB type who have limited effects by resynchronization.
Limitations
Measurement of QRS duration and the categorization of LBBB was left to the individual physician, and misclassification may have occurred. We have no information regarding the presence of RBBB but only whether patients had LBBB or not. Categories used in the registry, in particular LVEF, allowed no perfect match with selection criteria in the guidelines. We sought to accommodate this by evaluating guideline adoption in different scenarios with progressively stricter CRT selection criteria. In addition, we could not assess whether patients with potential CRT indication had contraindications. The analysis of CRT utilization represents only a snap-shot of CRT prevalence. and we cannot rule out that patients without CRT may have received CRT during the later course of follow-up or that they improved such that CRT was no longer indicated. However, follow-up referral to cardiologists and HF nurse clinics was rare, suggesting that most patients were not considered for CRT by the clinician responsible. Furthermore, since only a minor portion of CRT candidates had received a device, it is unlikely that this portion had greatly increased during further follow-up. We reported all-cause but not cause-specific mortality. The latter may provide a stronger link between the pathophysiology of conduction delay and outcomes, but the former is more clinically . 
Conclusions
This study in a large national registry shows that QRS prolongation of both LBBB and non-LBBB type is an independent predictor of mortality in patients with HF and reduced LVEF. Importantly, the increase in mortality risk attributable to QRS prolongation was similar in those with NYHA class II and those with NYHA class III-IV, and remained significant even after adjustment for a large number of relevant confounders. Although many HF patients with prolonged QRS fulfil current guideline criteria, CRT appears to be underutilized particularly among NYHA class II patients.
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